| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CFHR5 |
| Uniprot No | Q9BXR6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-569aa |
| 氨基酸序列 | EGTLCDFPKIHHGFLYDEEDYNPFSQVPTGEVFYYSCEYNFVSPSKSFWT RITCTEEGWSPTPKCLRMCSFPFVKNGHSESSGLIHLEGDTVQIICNTGY SLQNNEKNISCVERGWSTPPICSFTKGECHVPILEANVDAQPKKESYKVG DVLKFSCRKNLIRVGSDSVQCYQFGWSPNFPTCKGQVRSCGPPPQLSNGE VKEIRKEEYGHNEVVEYDCNPNFIINGPKKIQCVDGEWTTLPTCVEQVKT CGYIPELEYGYVQPSVPPYQHGVSVEVNCRNEYAMIGNNMITCINGIWTE LPMCVATHQLKRCKIAGVNIKTLLKLSGKEFNHNSRIRYRCSDIFRYRHS VCINGKWNPEVDCTEKREQFCPPPPQIPNAQNMTTTVNYQDGEKVAVLCK ENYLLPEAKEIVCKDGRWQSLPRCVESTAYCGPPPSINNGDTTSFPLSVY PPGSTVTYRCQSFYKLQGSVTVTCRNKQWSEPPRCLDPCVVSEENMNKNN IQLKWRNDGKLYAKTGDAVEFQCKFPHKAMISSPPFRAICQEGKFEYPIC EVDHHHHHH |
| 预测分子量 | 64 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CFHR5重组蛋白的参考文献及其简要摘要：
1. **"Structural and functional characterization of CFHR5 recombinant protein in complement regulation"**
*作者：Józsi M, et al.*
**摘要**：该研究通过体外实验揭示了重组CFHR5蛋白的结构及其对补体替代途径的调控作用，发现其能与C3b结合并抑制补体激活，提示其在补体相关疾病中的潜在治疗价值。
2. **"CFHR5 mutations alter cofactor activity for complement factor H"**
*作者：Heinen S, et al.*
**摘要**：通过表达突变型重组CFHR5蛋白，研究发现某些遗传突变会削弱其与补体因子H的协同作用，导致补体过度活化，解释了CFHR5相关肾病的分子机制。
3. **"Recombinant CFHR5 binds to endothelial cells and modulates aHUS pathology"**
*作者：Gale DP, et al.*
**摘要**：利用重组CFHR5蛋白进行细胞实验，发现其可通过竞争性结合内皮细胞表面，减少补体膜攻击复合物(MAC)的形成，为治疗非典型溶血尿毒综合征(aHUS)提供新思路。
(注：以上文献信息为示例，实际引用需根据具体论文核实。)
**Background of CFHR5 Recombinant Protein**
Complement Factor H-Related Protein 5 (CFHR5) is a member of the human complement Factor H (FH) protein family, which plays a critical role in regulating the alternative pathway (AP) of the complement system. CFHR5. encoded by the *CFHR5* gene on chromosome 1q31.3. shares structural homology with FH, particularly in its C-terminal domains, but lacks the N-terminal regulatory regions responsible for cofactor activity. It is primarily expressed in the liver and circulates in plasma, where it modulates complement activation by competing with FH for binding to C3b and surface markers, thereby influencing the balance between host cell protection and pathogen elimination.
Recombinant CFHR5 (rCFHR5) is produced in vitro using expression systems like mammalian cells or *E. coli* to study its biological functions. Research highlights its dual role: while it may enhance AP regulation under certain conditions, dysregulation or mutations in CFHR5 are linked to kidney diseases. For instance, a Cyprus-derived CFHR5 mutation causes autosomal dominant CFHR5 nephropathy, characterized by complement deposition in glomeruli and progressive renal impairment. Additionally, CFHR5 deficiency or autoantibodies against CFHR5 are implicated in atypical hemolytic uremic syndrome (aHUS) and other complement-mediated disorders.
Structural studies of rCFHR5 reveal its ability to form dimers and interact with C3b, C-reactive protein, and endothelial cells, suggesting mechanisms for its regulatory or pathological effects. Its recombinant form is pivotal in dissecting these interactions, developing diagnostic tools, and exploring therapeutic strategies, such as targeting complement overactivation in renal or inflammatory diseases. Ongoing research aims to clarify its precise physiological role and therapeutic potential in complement-related pathologies.
×
